# Operational Protocol Intelligence Report
**Target Protocol:** `PROTOCOL_A004_AMEND_001` (Osteoarthritis Pain Study)

## 1. Timestamp Intelligence
Extracting procedures that carry time-sensitive constraints beyond the simple date of the visit.

| Procedure | Required Timestamp | Why Required |
|------------|-------------------|--------------|
| **Informed Consent** | `HH:MM` | Must prove IC was obtained *prior* to any study-specific procedures being performed. |
| **Pain and Placebo Training** | `HH:MM` | Must be timestamped prior to dispensing the daily pain diary to validate run-in data. |
| **Triplicate ECGs (Conditional)** | `HH:MM` | If QTcF > 500ms, the subsequent 3 ECGs must be documented exactly 5 minutes apart. |
| **Study Intervention Administered** | `HH:MM` | Required to anchor pharmacokinetic/safety events and calculate the 30-day post-dose AE follow-up window. |

---

## 2. Window Intelligence
Extracting protocol-mandated timeframes that must be strictly observed.

| Activity | Window | Source Section |
|-----------|---------|----------------|
| **Run-In Pain Diary Collection** | $\ge$ 14 consecutive days immediately prior to Visit 2 | Section 4 (Study Design) / SoA |
| **Prior IA Steroid Washout** | 30 days prior to Screening | Section 5.2 (Exclusion Criteria) |
| **SAE Follow-up** | 30 days post last dose | Section 8.3 (Adverse Events) |
| **Pregnancy Test Validity** | Within 24-48 hours prior to first dose | Section 8.2 (Pregnancy) / Footnotes |
| **Interim Study Visits (Visits 3a-8a)** | $\pm$ 3 days from calculated baseline | SoA Headers |
| **End of Study / Visit 9** | $\pm$ 5 days | SoA Headers |

---

## 3. Sequence Intelligence
Mandatory order of operations that, if violated, result in critical protocol deviations or invalidation of data.

| Step | Must Occur Before | Reason |
|--------|------------------|--------|
| **Informed Consent** | All Screening Procedures | Ethical and regulatory mandate. |
| **Pain and Placebo Training** | Pain Diary Dispensing | Subjects must know how to score pain before they start recording baseline data. |
| **Run-In Diary Completion** | Randomization (Visit 2) | Run-in data confirms baseline severity and compliance. Eligibility depends on it. |
| **Serum Pregnancy Test (WOCBP)** | Randomization / Dosing | Teratogenic risk. Cannot expose a pregnant subject to IP. |
| **OCT / Retinal Exam** | Randomization / Dosing | Cannot dose subjects with pre-existing macular edema (Exclusion Criteria). |
| **Baseline X-Ray Index Knees** | Randomization | Determines structural OA baseline for efficacy endpoints. |

---

## 4. Deviation Risk Review
Analysis of activities with high probability of causing deviations and strategies to prevent them.

| Activity | Risk Level | Why It Is Risky | Prevention Strategy |
|------------|-----------|----------------|--------------------|
| **14-Day Run-In Calculation** | HIGH | Coordinators often miscount the days or allow gaps in the diary. | Source worksheet must include a hard-coded grid requiring 14 consecutive checkboxes and a supervisor signature before randomization. |
| **Imaging Non-Index Knee** | HIGH | X-rays must be on the specific "index knee". Staff may accidentally order bilateral or wrong-side. | Bold warning on imaging orders: "SPECIFY INDEX KNEE ONLY". |
| **Missing Triplicate ECG** | HIGH | Often forgotten when the baseline ECG triggers an abnormal >500ms reading. | Embed the conditional logic directly into the ECG source form with an explicit "IF YES -> DO THIS" workflow. |
| **Contraception Counseling** | MED | Missing from SoA but required by Section 5.1 at every visit for WOCBP. | Add a mandatory checkbox to every Visit Worksheet for WOCBP subjects. |

---

## 5. Coordinator Readiness Review

### A. Critical Eligibility Assessments
| Assessment | Criteria Impacted | Risk |
|------------|------------------|------|
| **OCT/Retinal Exam** | Exclusion | Randomizing a subject with pre-existing ocular issues invalidates safety data and harms the patient. |
| **Daily ADP NRS 0-10 Diary** | Inclusion | Primary endpoint baseline is compromised if $<14$ days collected. |
| **ConMed Review** | Exclusion | Concomitant IA steroids within 30 days invalidate the OA baseline. |

### B. Critical Safety Assessments
| Assessment | Safety Impact | Risk |
|------------|--------------|------|
| **Serum Pregnancy Test** | Fetotoxicity | High liability if IP is dosed to a pregnant subject. |
| **12-lead ECG** | Cardiac Toxicity | Missing a prolonged QT interval risks subject cardiac events. |
| **Ophthalmology Assessment** | Ocular Toxicity | Longitudinal OCTs protect against drug-induced retinal degradation. |

### C. Critical Endpoint Assessments
| Assessment | Endpoint Impact | Risk |
|------------|----------------|------|
| **ADP NRS 0-10 Pain Score** | Primary Efficacy | Missing data points reduce statistical power of the primary endpoint. |
| **X-ray index knees** | Secondary Efficacy | Missing the final X-ray makes joint space narrowing impossible to measure. |
| **Gadolinium MRI** | Secondary Efficacy | Required for evaluating structural cartilage changes. |

---

## 6. Final Assessment

**Could a coordinator safely execute this protocol using the knowledge extracted?**

**Answer: READY**

**Explanation:**
The operational intelligence extracted goes far beyond a passive reading of the protocol. 
By defining strict **Sequence Intelligence**, the system prevents the coordinator from administering the pain diary *before* the placebo training is conducted. By defining **Timestamp Intelligence**, it ensures that ECG cascades (5 minutes apart) are captured legally. By flagging **Missing Procedures** (Contraception Counseling) and inserting them into the deviation prevention strategy, the system protects the site from common audit findings.

A senior CRC could take this exact report and flawlessly design the Source Worksheets, Delegation Logs, and Lab Requisitions necessary to run the trial safely, compliantly, and with an extremely low deviation rate.
